WO2006078581A3 - Inactivated pepsin fraction, pharmaceutical compositions, and methods for detecting and treating diseases - Google Patents

Inactivated pepsin fraction, pharmaceutical compositions, and methods for detecting and treating diseases Download PDF

Info

Publication number
WO2006078581A3
WO2006078581A3 PCT/US2006/001385 US2006001385W WO2006078581A3 WO 2006078581 A3 WO2006078581 A3 WO 2006078581A3 US 2006001385 W US2006001385 W US 2006001385W WO 2006078581 A3 WO2006078581 A3 WO 2006078581A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
detecting
pharmaceutical compositions
treating diseases
inactivated pepsin
Prior art date
Application number
PCT/US2006/001385
Other languages
French (fr)
Other versions
WO2006078581A2 (en
Inventor
Harry H Zhabilov
Original Assignee
Viral Genetics Inc
Harry H Zhabilov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viral Genetics Inc, Harry H Zhabilov filed Critical Viral Genetics Inc
Publication of WO2006078581A2 publication Critical patent/WO2006078581A2/en
Publication of WO2006078581A3 publication Critical patent/WO2006078581A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6481—Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

An inactivated pepsin fraction is disclosed, with pharmaceutical preparations and methods for preparing and using them for diagnostics and therapeutics.
PCT/US2006/001385 2005-01-18 2006-01-18 Inactivated pepsin fraction, pharmaceutical compositions, and methods for detecting and treating diseases WO2006078581A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64405405P 2005-01-18 2005-01-18
US60/644,054 2005-01-18

Publications (2)

Publication Number Publication Date
WO2006078581A2 WO2006078581A2 (en) 2006-07-27
WO2006078581A3 true WO2006078581A3 (en) 2007-03-08

Family

ID=36692764

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/001385 WO2006078581A2 (en) 2005-01-18 2006-01-18 Inactivated pepsin fraction, pharmaceutical compositions, and methods for detecting and treating diseases

Country Status (1)

Country Link
WO (1) WO2006078581A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080131487A1 (en) * 2006-11-30 2008-06-05 Dag Ommundsen Chymosin for the prevention and treatment of gastrointestinal disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLUMENFELD O.O.: "The Effect of Guanidine Hydrochloride on Crystalline Pepsin", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 235, no. 2, February 1960 (1960-02-01), pages 379 - 382 *

Also Published As

Publication number Publication date
WO2006078581A2 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
EP4050035A4 (en) Beta-coronavirus antigen, preparation method therefor and use thereof
EP4039706A4 (en) Cldn18.2-targeting antibody, preparation method therefor, and use thereof
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2008133938A3 (en) Targeted integration into the ppp1r12c locus
TW200716646A (en) (S)-N-methylnaltrexone
WO2007106744A8 (en) Anti-5t4 antibodies and uses thereof
AU2006272804A8 (en) Concentrated protein lyophilates, methods, and uses
WO2007037849A3 (en) Compositions and methods for the intraocular transport of therapeutic agents
TW200738270A (en) Method of treating depression using a TNFα antibody
WO2006085906A3 (en) Method for the direct detection of diagnostic rna
WO2007120334A3 (en) Methods and compositions for targeting polyubiquitin
MY171841A (en) Antibody formulation
WO2008060705A3 (en) Anti-dll4 antibodies and methods using same
WO2007030810A3 (en) Multiparameter whole blood monitor and method
WO2007033230A3 (en) Anti-cd3 antibody formulations
WO2007133290A8 (en) Anti-ox40l antibodies and methods using same
WO2008157378A3 (en) Rage fusion proteins
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
WO2007027805A3 (en) Method for generating anti-variable region monoclonal antibodies
WO2009118722A3 (en) Methods and compositions for oral administration of proteins
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
WO2007081896A3 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
WO2007127506A8 (en) Anti-ephrinb2 antibodies and methods using same
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2008022263A3 (en) Methods for lymph system imaging

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06718457

Country of ref document: EP

Kind code of ref document: A2